Literature DB >> 7726912

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.

C Caldas1, S A Hahn, L T da Costa, M S Redston, M Schutte, A B Seymour, C L Weinstein, R H Hruban, C J Yeo, S E Kern.   

Abstract

The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/Cdk-4 complexes, and is deleted or mutated in a variety of tumour types. We found allelic deletions of 9p21-p22 in 85% of pancreatic adenocarcinomas. Analysis of MTS1 in pancreatic carcinomas (27 xenografts and 10 cell lines) showed homozygous deletions in 15 (41%) and sequence changes in 14 (38%). These included eight point mutations (four nonsense, two missense and two splice site mutations) and six deletions/insertions, all accompanied by loss of the wild-type allele. Sequencing of MTS1 from primary tumours confirmed the mutations. Coexistent inactivations of both MTS1 and p53 was common and suggests that abnormal regulation of cyclin-dependent kinases may play an important role in the biology of pancreatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7726912     DOI: 10.1038/ng0994-27

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  271 in total

1.  Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2.

Authors:  L H Liu; W H Xiao; W W Liu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells.

Authors:  S Y Song; I M Meszoely; R J Coffey; J A Pietenpol; S D Leach
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

3.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 4.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 5.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

Review 6.  Update on familial pancreatic cancer.

Authors:  H T Lynch; R E Brand; C A Deters; R M Fusaro
Journal:  Curr Gastroenterol Rep       Date:  2001-04

7.  Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer.

Authors:  Sandra Baumgart; Elisabeth Glesel; Garima Singh; Nai-Ming Chen; Kristina Reutlinger; Jinsan Zhang; Daniel D Billadeau; Martin E Fernandez-Zapico; Thomas M Gress; Shiv K Singh; Volker Ellenrieder
Journal:  Gastroenterology       Date:  2011-11-10       Impact factor: 22.682

8.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

Review 9.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

10.  Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype.

Authors:  Philip J Mitchell; Elena Perez-Nadales; Denise S Malcolm; Alison C Lloyd
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.